Busulfan Sample Collection Study
Condition(s) studied
Investigational drug(s) / intervention(s)
MyCare Oncology Busulfan Assay Kit: This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
Study summary
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
Eligibility
Primary outcome measure(s)
- Method Comparison Study — Sample collection to take place over 1 year. Samples to be analyzed monthly.
The samples being collected according to the protocol, SBI-BSI-001, will be used to compare the quantitate determination of BSF in patient samples based on the immunoassay vs. LC-MS/MS methods .
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | Active Not Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | Active Not Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05711732 on ClinicalTrials.gov ↗ ← All trials in the USA